266 related articles for article (PubMed ID: 32169439)
1. Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies.
Song W; Zhang M
Clin Immunol; 2020 May; 214():108382. PubMed ID: 32169439
[TBL] [Abstract][Full Text] [Related]
2. Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T.
Yoon DH; Osborn MJ; Tolar J; Kim CJ
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364163
[TBL] [Abstract][Full Text] [Related]
3. Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma.
Hradska K; Kascak M; Hajek R; Jelinek T
Expert Rev Hematol; 2020 Apr; 13(4):375-392. PubMed ID: 32116068
[No Abstract] [Full Text] [Related]
4. Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
Xia Y; Medeiros LJ; Young KH
Blood Rev; 2016 May; 30(3):189-200. PubMed ID: 26699946
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint inhibitors in hematological malignancies.
Ok CY; Young KH
J Hematol Oncol; 2017 May; 10(1):103. PubMed ID: 28482851
[TBL] [Abstract][Full Text] [Related]
6. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.
Tsirigotis P; Savani BN; Nagler A
Ann Med; 2016 Sep; 48(6):428-439. PubMed ID: 27224873
[TBL] [Abstract][Full Text] [Related]
7. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies.
Wang H; Kaur G; Sankin AI; Chen F; Guan F; Zang X
J Hematol Oncol; 2019 Jun; 12(1):59. PubMed ID: 31186046
[TBL] [Abstract][Full Text] [Related]
9. [Immune-checkpoint and hemopathies].
Burroni B; Broudin C; Damotte D; Laurent C
Ann Pathol; 2017 Feb; 37(1):101-110. PubMed ID: 28161001
[TBL] [Abstract][Full Text] [Related]
10. [Not Available].
Pasqualini C; Rialland F; Valteau-Couanet D; Michon J; Minard-Colin V
Bull Cancer; 2018 Dec; 105 Suppl 1():S68-S79. PubMed ID: 30595201
[TBL] [Abstract][Full Text] [Related]
11. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS
J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011
[TBL] [Abstract][Full Text] [Related]
12. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
13. Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas.
Kasenda B; Kühnl A; Chau I
Expert Rev Hematol; 2016; 9(2):123-35. PubMed ID: 26581237
[TBL] [Abstract][Full Text] [Related]
14. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.
Buchbinder EI; Dutcher JP; Daniels GA; Curti BD; Patel SP; Holtan SG; Miletello GP; Fishman MN; Gonzalez R; Clark JI; Richart JM; Lao CD; Tykodi SS; Silk AW; McDermott DF
J Immunother Cancer; 2019 Feb; 7(1):49. PubMed ID: 30777131
[TBL] [Abstract][Full Text] [Related]
15. [Specific immunotherapies in the treatment of cancers].
Denis H; Davoine C; Bermudez E; Grosjean G; Schwager M; Ifrah N; Dahan M; Negellen S
Bull Cancer; 2019 Jan; 106(1):37-47. PubMed ID: 30638899
[TBL] [Abstract][Full Text] [Related]
16. A man with recurrent hypovolemic shock on anti-programmed cell death protein 1 treatment: Immune-related protein-losing enteropathy.
Lee SY; Kim MH; Jang M; Park Y; Cho BC
Eur J Cancer; 2018 Nov; 104():104-107. PubMed ID: 30342309
[No Abstract] [Full Text] [Related]
17. Autoimmune pancreatitis after nivolumab anti-programmed death receptor-1 treatment.
Dehghani L; Mikail N; Kramkimel N; Soyer P; Lebtahi R; Mallone R; Larger E
Eur J Cancer; 2018 Nov; 104():243-246. PubMed ID: 30454710
[No Abstract] [Full Text] [Related]
18. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
19. CAR-T cell therapy for patients with hematological malignancies. A systematic review.
Pasqui DM; Latorraca CDOC; Pacheco RL; Riera R
Eur J Haematol; 2022 Dec; 109(6):601-618. PubMed ID: 36018500
[TBL] [Abstract][Full Text] [Related]
20. The Role of Checkpoint Inhibitors and Cytokines in Adoptive Cell-Based Cancer Immunotherapy with Genetically Modified T Cells.
Gershovich PM; Karabelskii AV; Ulitin AB; Ivanov RA
Biochemistry (Mosc); 2019 Jul; 84(7):695-710. PubMed ID: 31509722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]